LOS ANGELES, Nov. 28, 2016 /PRNewswire/ -- Global Health Solutions has announced 510k FDA approval of PolyPlex Wound Dressing, a first of its kind, petrolatum based topical gel indicated for acute and chronic wound management. PolyPlex Wound Dressing employs Global Health Solutions' proprietary PermaFusion™ delivery system, first employed in its initial product offering, CurX Antimicrobial Gel. This first of its kind delivery system enables powerful protection against bacteria, fungi, and yeasts, all without insult or irritation to fragile, healing tissue. CurX and PolyPlex product developer and Global Health Solutions CEO, Bradley Burnam, states: "The need for innovation in acute and chronic wound care is critical, as antimicrobial resistance is at an all-time high. PolyPlex successfully balances potency with gentleness, eliminating frustrating tradeoffs in patient care that have plagued wound care practitioners for decades." Chronic wounds represent a significant burden to patients and practitioners, as well as the United States healthcare system, affecting 5.7 million patients and costing an estimated 20 billion dollars, annually. Glenn Mattes, Executive Chair of Global Health Solutions, states: "The approval and introduction of PolyPlex will provide practitioners with an important new wound management tool suitable for a multitude of patient types. We plan to aggressively market and sell PolyPlex, as well continue to develop and introduce additional products to this market." PolyPlex Wound Dressing will be available in January of 2017 through McKesson Medical-Surgical. For more information, contact your McKesson account manager or visit www.globalhealthrx.com.